Immunosenescence is far more than a simple decline in immune vigor. It is a sweeping remodeling of both the innate and adaptive arms of immunity, marked by a shrinking pool of naive T cells, an accumulation of exhausted memory cells, a narrowing of T-cell receptor diversity, and a chronic, low-grade inflammatory state often called inflammaging. These changes are closely tied to impaired immunometabolism, mitochondrial dysfunction, and shifts in key signaling networks, including the AMPK/mTOR axis, the NF-kappaB pathway, autophagy, and the NLRP3 inflammasome. Because no single molecular defect drives the process, the authors contend that a multi-target agent may be better suited to intervene than highly specific drugs aimed at one pathway at a time.

Berberine, an isoquinoline alkaloid extracted from plants such as Berberis vulgaris, has been used in traditional Chinese and Ayurvedic medicine for centuries. Modern pharmacology has mapped an impressive array of its molecular actions: it activates AMP-activated protein kinase (AMPK) partly by inhibiting mitochondrial respiratory complex I, suppresses mTOR signaling, modulates NF-kappaB-driven inflammation, promotes autophagy, and inhibits NLRP3 inflammasome activation. Each of these targets sits squarely at the intersection of the pathways that go awry during immunosenescence. Clinical evidence already supports berberine’s benefits in cardiometabolic disease, including type 2 diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, and a phase 2 trial of berberine ursodeoxycholate showed proof of concept in patients with non-alcoholic steatohepatitis and type 2 diabetes.

The review assembles evidence from cellular, animal, and early human studies that speaks directly to immune aging. In cell culture, berberine suppresses gero-conversion, the transition from reversible cell-cycle arrest to full senescence, and protects cells from oxidative stress-induced senescence through AMPK activation, restoration of autophagic flux, and elevation of intracellular NAD+. In mice, the compound ameliorates cellular senescence and extends lifespan by regulating p16 and cyclin protein expression. In simpler organisms, berberine prolongs lifespan and stimulates locomotor activity in Drosophila melanogaster and extends lifespan in Caenorhabditis elegans through multi-target antioxidant effects and ROS-dependent activation of the PMK-1/SKN-1 stress-response pathway.

Particularly relevant to immune aging are berberine’s documented effects on inflammatory signaling. The compound inhibits LPS-induced inflammatory responses through the NF-kappaB pathway, blocks NLRP3 inflammasome activation in macrophages by triggering autophagy and regulating the mTOR/mitochondrial ROS axis, and reduces SASP-related inflammation through the RXRalpha/PPARgamma/NEDD4 pathway in models of atherosclerosis. It also modulates sirtuin 1 activity, a deacetylase implicated in immune cell longevity, and enhances innate antiviral defenses via the p38 MAPK pathway, with demonstrated anti-influenza activity in mice. Because the senescence-associated secretory phenotype, or SASP, is a major driver of chronic age-related inflammation, a drug that dampens SASP output while simultaneously supporting autophagy and mitochondrial quality control addresses several hallmarks of immune aging at once.

The review also highlights a newer generation of berberine derivatives engineered to overcome the parent compound’s most stubborn limitation: poor oral bioavailability. Berberine is poorly absorbed from the gut, relies partly on gut microbiota transformation into the intestine-absorbable form dihydroberberine, and is subject to efflux by P-glycoprotein. Chemists have responded with 8,8-dimethyldihydroberberine, 9-O-substituted and 9-N-alkyl derivatives, liposomal and nanoparticle formulations, and self-microemulsifying delivery systems, all of which improve absorption in animal or human studies. Some derivatives add entirely new capabilities: a 13-decyl berberine derivative has been described as a novel mitochondria-targeted antioxidant and potent inhibitor of ferroptosis, while tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy, and berberrubine-based mitorubin compounds improve mitochondrial function and protect against age-related cardiac dysfunction.

Yet the authors are careful to temper enthusiasm with critical caveats. Much of the immunosenescence-relevant evidence comes from in vitro work or from animal models whose immune systems differ substantially from aged humans. Direct clinical trials testing berberine specifically against immunosenescence biomarkers, such as T-cell receptor repertoire diversity, p16INK4a expression in peripheral blood T cells, senescence-associated beta-galactosidase in CD8+ T cells, or inflammatory aging clocks like iAge, have not been performed. Safety considerations also warrant attention: berberine inhibits cytochrome P450 enzymes in humans, raising drug-interaction risks, and it has been shown to alter blood levels of immunosuppressants such as cyclosporin A in transplant recipients. Its interaction with the adenine nucleotide translocator and complex I inhibition, while mechanistically central to AMPK activation, could be a double-edged sword in metabolically stressed immune cells.

To move the field forward, the review proposes a framework for future studies. The authors call for properly designed experiments in aged animal models that measure established immunosenescence biomarkers rather than generic inflammation endpoints, followed by carefully monitored human trials in older populations. They emphasize the value of modern immune-aging metrics, including single-cell immune aging clocks that capture inter-individual heterogeneity during infection and vaccination, and suggest that derivatives with improved bioavailability and mitochondrial targeting should be prioritized. Vaccine responsiveness in the elderly, which is notoriously blunted and linked to T-cell autophagy decline, is identified as a clinically meaningful outcome that a berberine-based intervention could plausibly improve.

The broader significance of the analysis lies in its reframing of an old herbal medicine as a systems-level geroprotector. Where most anti-aging pharmacology pursues single targets, berberine’s pleiotropy, acting simultaneously on energy sensing, inflammatory transcription, autophagy, inflammasome activity, and mitochondrial function, mirrors the interconnected nature of immune aging itself. Whether that pleiotropy translates into safe and measurable rejuvenation of the human immune system remains an open question, but the review provides the mechanistic rationale and the experimental roadmap needed to find out. If subsequent trials validate the promise, a compound once confined to traditional apothecaries could become a cornerstone of interventions designed to keep aging immune systems, and the aging populations they protect, healthier for longer.

Subject of Research: Evaluation of berberine and its derivatives as multi-target modulators of age-related immune system decline (immunosenescence).

Article Title: Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation

Article References: Zinovkin, R. A., Lyamzaev, K. G., Churov, A., Maltseva, O., & Wu, Z. (2026). Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation. Biogerontology, 27(5), Article 153. https://doi.org/10.1007/s10522-026-10504-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10504-2

Keywords: berberine, immunosenescence, aging, AMPK, mTOR, NF-kappaB, autophagy, NLRP3 inflammasome, inflammaging, mitochondria, berberine derivatives, geroprotection

The core of the argument is that mitochondria are not static energy factories. They integrate oxidative metabolism with redox signalling, calcium handling, biosynthesis, apoptosis, innate immunity, and constant communication with other organelles. What determines whether an aged tissue retains function, the review contends, is not the raw abundance of mitochondria or their resting respiration, but the network’s ability to sustain itself under stress. Maintenance safeguards the mitochondrial genome, proteome, and membrane integrity. Adaptation adjusts metabolism and remodels network and cristae architecture to match changing demand. Recovery restores function and reserve after a challenge such as exercise, infection, or injury. Ageing, in this view, contracts the range over which these transitions can occur, even when basal measurements look deceptively normal.

Take the mitochondrial genome. The review synthesises evidence showing that the accumulation and clonal expansion of mtDNA mutations during ageing arise predominantly from replication error rather than oxidative damage, overturning a long-standing assumption. Heteroplasmic variants can remain functionally silent until their proportion crosses mutation- and tissue-specific biochemical thresholds, and mutation load alone does not determine mitochondrial failure. Recent work adds a provocative twist: ribonucleotide incorporation into mitochondrial DNA can drive inflammatory signalling, meaning that defective genome maintenance has consequences well beyond impaired oxidative phosphorylation. When damaged mitochondrial DNA or RNA leaks into the cytosol of senescent cells, it activates innate immune pathways including cGAS-STING and the NLRP3 inflammasome, reinforcing the senescence-associated secretory phenotype and feeding the chronic low-grade inflammation known as inflammageing.

Proteostasis is equally central. The human mitochondrial proteome exceeds one thousand proteins, most encoded in the nucleus, imported into the organelle, and assembled into complexes under the surveillance of chaperones, ATP-dependent proteases, ribosome quality control, the mitochondrial unfolded protein response, and mitophagy. This network matters most in long-lived postmitotic cells such as neurons and cardiomyocytes, where cumulative proteotoxic stress cannot be diluted by cell division. Strikingly, cryoelectron tomography studies have recently linked an age-related decline in mitoribosome abundance and organisation in primary human T cells to impaired mitochondrial biogenesis and reduced cellular function, illustrating how organelle translation can become a cell-type-specific bottleneck in human ageing.

The review is emphatic that neither fragmentation nor elongation of mitochondrial networks is intrinsically good or bad. Experimental manipulation of either fission or fusion can extend lifespan in model organisms under specific conditions, which undermines the habit of treating one morphology as a universal marker of mitochondrial health. The more informative property is network plasticity, the capacity to remodel appropriately. Human studies back this up: three-dimensional imaging of aged skeletal muscle shows that age-related changes in mitochondrial architecture correlate with muscle characteristics, and that mitochondrial fragmentation predicts age-associated decline in physical capacity. Exercise appears to preserve aspects of mitochondria–endoplasmic reticulum contact-site organisation, while recent mechanistic work shows that mitochondrial calcium uptake declines with ageing and directly constrains muscle performance, a finding with implications for how energetic reserve, rather than basal respiration, should be assessed.

Mitophagy, the selective removal of damaged mitochondria, emerges as another domain where quantity is the wrong metric. Suppression of basal mitophagy can drive cellular ageing phenotypes in primary cells, and coordination between mitophagy and biogenesis, regulated by PGC-1 coactivators and TFAM, is necessary for organismal adaptation during ageing. The translational issue is turnover quality, not maximal turnover rate: excessive elimination without adequate replacement reduces energetic capacity, while biogenesis without effective quality control simply expands a dysfunctional pool. Crucially, enhanced mitophagy can restrain the cGAS-STING inflammatory axis in ageing models, positioning mitochondrial housekeeping as an anti-inflammatory intervention in its own right.

This is where the framework becomes provocative for the booming longevity industry. The review systematically evaluates candidate interventions and finds the human evidence strikingly lopsided. Exercise provides the strongest human evidence for coordinated mitochondrial and functional adaptation, engaging all three homeodynamic domains at once as a repeated multidimensional challenge followed by recovery. Energy restriction improved cardiometabolic risk factors in the CALERIE trial but never tested human lifespan. NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide reliably raise NAD+-related metabolites, yet their effects on metabolic, vascular, inflammatory, and functional outcomes remain inconsistent; biochemical target engagement, the review insists, establishes biological activity rather than geroprotection. Urolithin A produced molecular evidence of mitophagy engagement and improved selected muscle-endurance outcomes in a randomized trial of older adults, while spermidine supplementation failed to improve its primary cognitive endpoint. MitoQ improved endothelial function in a small study, and elamipretide acutely increased muscle ATP production but flopped in a longer heart-failure trial. Notably, metformin attenuated some exercise-induced mitochondrial adaptations in older adults, a caution that a drug can engage a plausible target while blunting the response to a stimulus of established benefit.

The review’s most quotable conclusion is unambiguous: no mitochondrial intervention has been shown to slow ageing or extend lifespan in healthy humans, and the movement of a biomarker towards a younger reference value does not establish rejuvenation. Circulating markers such as GDF15 and FGF21, which rise with age and report activation of the mitochondrial integrated stress response, are confounded by inflammation, renal function, malignancy, and common medications including metformin. They report that a stress pathway is active, not that the underlying capacities are preserved.

To guard against circularity, Chmielewski frames the concept as three falsifiable predictions. First, among individuals matched for age, sex, and resting mitochondrial capacity, the amplitude and rate of recovery after a standardised physiological challenge should predict subsequent functional decline, whereas resting measures alone should predict it less well or not at all. Second, an intervention that improves resting biomarkers without improving adaptation or recovery should not deliver the functional outcomes attributed to its mitochondrial action. Third, because the limiting domain differs across tissues and individuals, the response to a domain-specific intervention should be predictable from which domain is limiting at baseline. If measures of adaptation and recovery add no predictive information beyond resting phenotypes, the framework should, by its own logic, be abandoned.

The implications for precision geroscience are considerable. Because skeletal muscle, heart, neurons, immune cells, and haematopoietic stem cells face entirely different constraints, the review argues against a single mitochondrial ageing score unless its components are explicitly tissue-aware. Even in stem cells, mitochondrial abundance identifies states with distinct self-renewal properties rather than functioning as a simple damage marker, so the relevant phenotype is the ability to transition between metabolic states, not maximal output in one of them. Sex modifies mitochondrial phenotypes too: human blood-cell respiration differs by sex across age and can even increase with age, complicating any assumption of uniform decline.

The practical obstacle is measurement. Standardised challenge-based phenotyping, quantifying respiratory reserve, substrate switching, mitophagic flux, redox recovery, and functional performance after exercise, metabolic stress, or vaccination, remains to be validated for reproducibility, tissue specificity, and prediction of clinical outcomes. Muscle biopsy permits detailed phenotyping but is invasive; blood-based assays may not represent brain, heart, or muscle. The review sets out five priorities for the field, including identifying which measurements reproducibly capture the three domains in humans, and determining whether they predict functional decline independently of chronological age and established risk factors.

The conclusion is a measured reframing rather than a breakthrough claim. Mitochondrial ageing, the review argues, is best described as erosion of coordinated maintenance, adaptation, and recovery, not uniform loss of ATP production or simple oxidative stress. Mitochondrial changes may be initiating, amplifying, compensatory, or consequential depending on tissue and context, and more mitochondrial activity is not invariably beneficial; the objective is regulated flexibility rather than maximisation. For a field saturated with promises of youthful NAD+ levels and mitochondrial rejuvenation, the message is sobering but constructive: preserve adaptive capacity and function without disrupting compensatory biology, and judge interventions by recovery kinetics and clinically meaningful outcomes, not by biomarkers drifting towards a younger reference range.

The announcement arrives as longevity research moves rapidly from an academic discipline into a highly financed biomedical sector. Aging is no longer viewed solely as an unavoidable background process that increases the risk of individual diseases. Instead, scientists increasingly describe it as a complex biological state shaped by interacting mechanisms, including genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence, chronic inflammation, impaired protein quality control, and the progressive loss of regenerative capacity. These mechanisms influence one another across tissues and organs, helping explain why cardiovascular disease, cancer, neurodegeneration, frailty, and metabolic disorders become more common with age. The central scientific challenge is determining which components of this network can be safely modified in humans.

At ARDD 2026, that challenge will be examined through the lens of translational medicine: the process of moving from molecular insight to measurable clinical benefit. A successful longevity intervention would need to do more than improve a laboratory marker or extend the lifespan of an experimental animal. It would have to demonstrate a meaningful effect on human health, such as delaying multiple age-associated diseases, preserving physical and cognitive function, or extending the period during which individuals remain independent. Researchers are therefore developing increasingly sophisticated methods to evaluate biological aging, including epigenetic clocks, proteomic profiles, immune-system measurements, imaging technologies, functional assessments, and composite indicators of physiological resilience. The usefulness of these biomarkers will ultimately depend on whether they predict clinical outcomes and respond reliably to treatment.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, Executive Chair of ARDD and Professor of Medicine at Harvard University. He emphasized that understanding the mechanisms of aging must be paired with the development of interventions that improve healthspan, the portion of life spent in good health. This distinction is critical. A therapy that increases survival without preserving mobility, cognition, or quality of life would offer limited value, while an intervention that delays several chronic diseases could transform preventive medicine. The field is consequently attempting to define new therapeutic endpoints and trial designs that can capture broad effects across the aging process without requiring decades of follow-up.

The conference will also reflect the growing involvement of major pharmaceutical companies, which are increasingly exploring whether aging-related mechanisms can become druggable targets. Large-scale drug discovery depends on identifying biological pathways that can be modified with sufficient precision and safety. Potential strategies include eliminating senescent cells that accumulate inflammatory signals, restoring impaired mitochondrial function, modulating nutrient-sensing pathways, improving DNA repair, reducing chronic inflammation, enhancing cellular recycling through autophagy, and using regenerative approaches to maintain tissue function. Each approach carries substantial scientific risks. Aging is not governed by a single switch, and pathways that promote tissue repair or growth early in life may contribute to cancer or metabolic dysfunction when activated excessively later in life.

ARDD Co-Chair Morten Scheibye-Knudsen, Associate Professor at the University of Copenhagen, said the meeting’s relocation to Boston represents a new chapter for the event by placing it within one of the world’s most concentrated biomedical innovation ecosystems. The region’s universities, hospitals, biotechnology companies, pharmaceutical laboratories, venture-capital firms, and research institutes create an environment in which discoveries can move quickly between basic science and clinical development. That proximity is particularly important for longevity research, where the most promising ideas often emerge from fields that have traditionally operated separately, including genetics, gerontology, immunology, oncology, neuroscience, metabolism, data science, and drug development.

Artificial intelligence is expected to remain an important part of this convergence. Machine-learning systems can analyze large collections of genomic, transcriptomic, proteomic, imaging, and clinical data to identify patterns associated with biological aging and disease risk. In drug discovery, generative models can propose new molecular structures, predict how compounds may interact with biological targets, and help prioritize experiments. Insilico Medicine, which officially organizes the 2026 meeting, has positioned artificial intelligence as a central component of its approach to pharmaceutical research. However, computational predictions still require rigorous laboratory validation, toxicology testing, and controlled clinical trials. The speed of algorithmic design does not remove the biological complexity of aging or the regulatory standards required for human medicines.

The 2026 meeting is anchored by Tier 1 sponsors Insilico Medicine and Eli Lilly, with the McKinsey Health Institute serving as Sole Knowledge Partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, TruDiagnostic, Synaro Capital, The Cat Health Company, PranaGen Bioscience, Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope. The breadth of this participation illustrates how longevity science now intersects with pharmaceuticals, diagnostics, nutrition, consumer health, finance, artificial intelligence, and preventive-care services.

Alex Zhavoronkov, Ph.D., Co-Chair of ARDD and CEO of Insilico Medicine, described the meeting as a platform for dialogue among academia, pharmaceutical companies, startups, and investors. That dialogue may become increasingly important as the field confronts questions that cannot be answered by laboratory science alone. Investigators must determine which biomarkers are acceptable to regulators, how clinical trials should select participants, whether interventions should target healthy adults or individuals already showing functional decline, and how long-term safety should be monitored. Investors and companies, meanwhile, must distinguish between biologically plausible programs and products supported by reproducible human evidence. These decisions will shape whether longevity biotechnology develops into a durable medical discipline or remains dominated by unverified claims.

The ARDD Meeting, now in its 13th year, is described as the world’s largest gathering dedicated to aging and longevity biotechnology. Its 2026 edition will bring together researchers, clinicians, biotechnology and pharmaceutical leaders, entrepreneurs, investors, and policymakers to examine the path from fundamental discoveries to practical research and development programs. The Nordic Aging Society, a nonprofit scientific organization focused on the biology of aging and collaboration across the Nordic region and beyond, is supporting the event. As the meeting approaches, the attention surrounding it reflects a broader shift in medicine: aging is increasingly being studied not simply as a statistic or an inevitable decline, but as a biological process whose consequences may be delayed, measured, and potentially modified through carefully tested interventions.

Subject of Research: Aging biology, longevity biotechnology, healthspan extension, and the translation of aging research into therapeutic drug-development programs.

Article Title: Aging Science Moves Toward the Clinic as ARDD 2026 Brings Longevity Research to Boston

News Publication Date: August 14, 2026

Web References: agingpharma.org

Image Credits: ARDD 2026

Keywords: aging research, longevity science, healthspan, drug discovery, biotechnology, biological aging, senescence, epigenetic clocks, artificial intelligence, ARDD 2026, Insilico Medicine, pharmaceutical research, preventive medicine, Harvard University

ARDD 2026 arrives as longevity research moves beyond speculative discussions about extending lifespan and toward a more technically defined goal: extending healthspan, the period during which people remain free from major age-related disease and disability. Researchers are increasingly studying aging as a complex biological process involving cellular senescence, chronic inflammation, mitochondrial dysfunction, impaired protein quality control, genomic instability, and changes in tissue repair. The convergence of these fields has created new opportunities for drug discovery, biomarker development, and clinical testing.

The meeting is expected to bring together academic scientists, clinical investigators, biotechnology companies, pharmaceutical executives, entrepreneurs, investors, and policymakers. Its organizers describe the event as a global forum for translating discoveries in the biology of aging into therapeutic programs. That translation remains one of the field’s central challenges: findings observed in model organisms must be validated in humans, measurable biological markers must be linked to meaningful clinical outcomes, and potential interventions must demonstrate acceptable safety over long treatment periods.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He emphasized that progress will require collaboration across disciplines and sectors. Aging biology draws on genetics, molecular biology, systems medicine, computational science, epidemiology, and clinical research, making partnerships essential for determining which mechanisms are genuinely actionable and which are only correlated with age-related decline.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the conference’s move to Boston represents a new chapter for the meeting. Boston and the broader northeastern United States host a dense network of universities, hospitals, biotechnology companies, venture investors, and pharmaceutical research centers. The location is intended to connect longevity researchers with an ecosystem already known for developing therapies in oncology, immunology, metabolic disease, and neurology—fields that increasingly intersect with the science of aging.

The 2026 meeting will be officially organized by Insilico Medicine, with Insilico Medicine and Eli Lilly serving as Tier 1 sponsors. The McKinsey Health Institute will participate as the sole knowledge partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, and TruDiagnostic. Other supporting organizations include Synaro Capital, The Cat Health Company, PranaGen Bioscience, Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope.

The breadth of this sponsor network reflects the increasingly commercial character of longevity science. Companies are developing interventions aimed at specific mechanisms associated with aging, including senescent cell accumulation, immune aging, metabolic deterioration, extracellular matrix changes, and loss of muscle strength. Others are building technologies to measure biological age using DNA methylation, proteomic signatures, glycan profiles, imaging, and functional assessments. These tools could help researchers identify high-risk individuals, select participants for clinical trials, and determine whether a treatment is altering the underlying biology rather than merely easing symptoms.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and CEO of Insilico Medicine, said the meeting has served for more than a decade as a platform connecting academia, pharmaceutical companies, startups, and investors. He described the momentum surrounding the 2026 event as evidence that longevity biotechnology has become an important part of modern drug discovery and health economics. Insilico Medicine has been among the companies applying artificial intelligence to target identification and drug design, a strategy that could accelerate the search for compounds capable of modulating disease-related aging pathways.

Now in its 13th year, ARDD is presented by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 program is expected to focus on the practical requirements of developing therapies: defining robust biomarkers, designing trials for slowly progressing conditions, identifying clinically meaningful measures of function, and establishing regulatory pathways for interventions that target aging-related biology. As the field enters a more mature phase, its credibility will increasingly depend on reproducible evidence, rigorous human studies, and the ability to show that molecular improvements translate into longer, healthier lives.

Subject of Research: Aging biology, longevity biotechnology, healthspan extension, and the translation of aging research into therapeutic drug-development programs.

Article Title: ARDD 2026 to Bring Pharmaceutical and Longevity Leaders Together in Boston

News Publication Date: August 7, 2026

Web References: agingpharma.org

Image Credits: ARDD 2026

Keywords: aging research, longevity science, healthspan, geroscience, drug discovery, biotechnology, Eli Lilly, Insilico Medicine, ARDD 2026, biological aging, senescence, biomarkers, Harvard University